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Abstract
Non-alcoholic fatty liver disease (NAFLD) refers to fatty infiltration of liver
in the absence of significant alcohol intake, use of steatogenic medication,
or hereditary disorders. It is a common cause of chronic liver disease with
a worldwide estimated prevalence ranging from 6.3% to 33%. The NAFLD is
considered a hepatic manifestation of the metabolic syndrome. Insulin resistance and increased oxidative stress are central to pathogenesis of NAFLD,
and risk factors include metabolic syndrome, diabetes mellitus, obesity, lack
of physical activity, smoking, and high fat diet. NAFLD is associated with
higher mortality as compared to the general population with cardiovascular
disease being the most common cause of death. The NAFLD is associated
with a higher prevalence of subclinical atherosclerosis as evidenced by odds
of higher coronary artery calcification, higher average and maximum carotid
intima-media thickness. It is also associated with stiff arteries as evidenced
by higher cardio-ankle vascular index and higher brachial-ankle pulse wave
velocity. Increasing evidence has linked NAFLD with atherosclerotic cardiovascular diseases. The NAFLD is associated with a higher prevalence of
coronary artery disease (CAD), more severe CAD, poor coronary collateral
development, and higher incidence of coronary events. The NAFLD is also
associated with ischemic stroke. Studies have shown that the association
between NAFLD and atherosclerotic cardiovascular diseases is independent
of shared risk factors.
Key words: non-alcoholic fatty liver disease, coronary artery disease,
atherosclerotic cardiovascular disease.

Introduction
Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic
liver disease with increasing worldwide prevalence. Non-alcoholic fatty
liver disease is defined by imaging or histological evidence of fatty infiltration of liver in the absence of known causes of fat accumulation in
the liver including significant alcohol consumption [1]. Non-alcoholic fatty
liver disease is a spectrum of disease ranging from simple steatosis (NAFL
or non-alcoholic fatty liver) without evidence of hepatocellular injury to
non-alcoholic steatohepatitis (NASH) marked by inflammation with hepatocyte injury with or without fibrosis [1, 2]. Non-alcoholic fatty liver disease may or may not be associated with aminotransferase elevation [1].
Due to widespread availability and low cost, ultrasound is the preferred initial radiological study to assess for fatty infiltration of liver [3, 4].
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Non-alcoholic steatohepatitis represents more advanced stage of the disease and has an inflammatory component in addition to fat accumulation [1]. Non-alcoholic steatohepatitis may further
progress to cirrhosis and or to hepatocellular carcinoma [5]. Various non-invasive methods such as
the NAFLD fibrosis score [6], Enhanced Liver Fibrosis (ELF) panel, presence of circulating biomarkers
(cytokeratin-18) can identify advanced fibrosis
[7]. However, liver biopsy is the ‘gold standard’ for
assessing the histology in NAFLD and accurately
identifying NASH. Metabolic syndrome predicts
the presence of steatohepatitis in NAFLD patients
and its presence should guide the decision to obtain liver biopsy [1].
Non-alcoholic fatty liver disease is sometimes
referred to as the hepatic manifestation of metabolic syndrome [8, 9]. It is associated with higher
overall mortality as compared to the general population [10, 11]. Cardiovascular diseases are the
most common cause of death among patients
with NAFLD [9–11] while liver disease is the third
leading cause [11, 12]. The aim of this paper is to
review the available literature linking NAFLD and
cardiovascular disease.
Because of shared risk factors with the metabolic syndrome, NAFLD was considered as a mere
marker of cardiovascular disease. However, studies are available that show an association between
cardiovascular disease and NAFLD independent of
shared risk factors [13–16].

Epidemiology
The reported incidence of NAFLD varies widely. A retrospective analysis reported an annual
incidence of 29 per 100,000 patient years [17].
Another prospective study in a Japanese population reported 308 new cases among 3147 patients during a 414 days follow-up period [18].
The wide variation in reporting indicates the
need for a better study to calculate the actual
incidence rates.
The prevalence of NAFLD has been increasing in
recent times. The reported prevalence varies based
on the population studied and modality used to
establish the diagnosis. The worldwide prevalence
in the general population ranges from 6.3% to
33% with a median of 20% [1]. The prevalence
is much higher in a high-risk patient population.
Machado et al combined 12 observational studies including 1620 patients with morbid obesity
and reported a 91% prevalence (range: 85–98%)
of NAFLD in this population group [19]. Two separate studies quoted a prevalence of ultrasonographic NAFLD in diabetic patients at 69.4% [20]
and 67.8% [21]. Another study in patients referred
to a urban hospital-based lipid clinic showed
a NAFLD prevalence of 50% [22].
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Etiopathogenesis and risk factors
Day and James explained the pathogenesis
of NAFLD in 1998 by ‘two-hit hypothesis’ [23].
The first physiological event is insulin resistance.
Insulin resistance manifests not only at the level of muscles but also at the level of liver and
adipose tissue [24]. The combined effect of hyperinsulinemia and insulin resistance leads to
an increased absolute hepatic free fatty acid uptake and increased esterification to triglycerides
among other mechanisms leading to hepatic
steatosis [25]. It should be stressed that insulin
resistance is a cause of NAFLD rather than being
its effect as shown by studies in genetically predisposed NAFLD subjects who have insulin sensitivity comparable to matched subjects without
NAFLD [26–28].
The second physiological event is increased oxidative stress [25, 29]. Oxidative stress plays a dual
role by contributing to steatosis due to higher peroxidation of lipids and by promoting progression
of steatosis to steatohepatitis. A study has shown
a higher rate of lipid oxidation and impaired suppression of hepatic lipid oxidation by insulin in
patients with NAFLD [24].
With better understanding of the pathogenesis of NAFLD, a ‘multiple parallel hits’ hypothesis
has gained more acceptance [30, 31]. Insulin resistance and its metabolic disturbance constitute
the first hit resulting to fat infiltration of liver. This
is followed by multiple parallel hits, leading to hepatocyte injury and progression from simple steatosis to NASH and fibrosis [30].
Cytokines play an important role in insulin resistance and NAFLD [32]. Higher levels of pro-inflammatory cytokine tumor necrosis factor-α (TNF-α)
are associated with increased insulin resistance
[33]. Mice lacking TNF-α were shown to have improved insulin sensitivity [34]. Haukeland et al.
demonstrated higher levels pro-inflammatory cytokines interleukin-6 (IL-6), chemokine ligand 2/
monocyte chemoattractant protein-1 (CCL-2/
MCP-1), TNF-α and decreased level of adiponectin
among patients with NAFLD compared to controls
[35]. IL-6 expression is markedly increased in patients with NASH as compared to patients with
NAFLD or normal liver histology [36]. Anti-inflammatory adipocytokine adiponectin levels are lower
in patients with hepatic steatosis and NASH [37].
Obesity has a strong correlation with insulin
resistance and NAFLD [38–40]. The prevalence of
NAFLD among morbidly obese patients based on
a meta-analysis was 91% (range: 85–98%) [19].
There is evidence that weight loss among obese
patient with type II diabetes mellitus can normalize insulin sensitivity [41]. Another study showed
that weight loss can prevent progression of glucose intolerance to type II diabetes mellitus [42].
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Choudhary et al. prospectively studied 16 living related liver donors with significant steatosis
based on liver histology. Donors were recommended 1200 Kcal/day diet and 60 min/day moderate
cardiovascular training. Repeat liver biopsy done at
28 ±10 days showed a decrease in steatosis in all
but one subject including normalization of the liver
biopsy in 7 donors [43]. A review of the literature of
bariatric surgery showed significant improvement
and resolution of steatosis with bariatric surgery
[44]. However, in patients with established hepatic
fibrosis, there are conflicting data about the outcome of metabolic procedures. Some studies have
shown that metabolic procedures are associated
with worsening of fibrosis in patients with advanced fibrosis [45, 46]. However, a few including
prospective studies have also shown improvement
in fibrosis after a bariatric procedure [45, 47].
The use of exercise is a well-established prevention and therapeutic recommendation for
NAFLD [48]. Increased physical activity not only
plays a protective role against many risk factors of
NAFLD such as obesity, metabolic syndrome, hyperlipidemia, and insulin resistance, but also has
independent beneficial effects. In a cross-sectional study, physical activity was inversely proportional to the prevalence of NAFLD in a dose dependent
manner that was independent of visceral obesity
and insulin resistance [49]. Another cross-sectional analysis of non-diabetic Korean individuals
showed that regular exercise was associated with
a reduced risk of having NAFLD and decreased liver enzymes in patients with NAFLD [50].
Smoking has been implicated as a risk factor
for NAFLD in several case control studies. Three
separate studies in a Chinese population has established cigarette smoking as risk factors and
its interaction with genetic polymorphisms of
MCP-1 receptor CCR2 gene 190A/G (GG), NADPH
oxidase subunit p22phox gene C242T [51], LEPR
gene Gln223Arg, MnSOD9Ala/Val [52], AdipoR2
gene +33371Gln/Arg, and CYP2E1-Rsa I [53], increasing the risk even further. The odds of cases
being smokers as compared to controls in these
three studies were 3.3032 [51], 3.6754 [52], and
2.5919 [53].
High fat diet is a precursor for insulin resistance
[54] and a risk factor for NAFLD. Wiedemann et al.
showed induction of hepatic insulin resistance by
4 days of a high fat diet (52% fat calories) in mice
[55]. Pan et al. have shown that more than 70% of
mice that were a fed high fat diet (42% fat calories) developed NAFLD at 12 weeks [56].

Non-alcoholic fatty liver disease and
subclinical atherosclerosis
Insulin resistance is the cornerstone of NAFLD
pathogenesis and is closely associated with the

metabolic syndrome. Non-alcoholic fatty liver disease, insulin resistance, and the metabolic syndrome share multiple risk factors. Some authors
have referred to NAFLD as a hepatic manifestation
of the metabolic syndrome. Non-alcoholic fatty liver disease accelerates development and progression of atherosclerosis. However, disagreement
exists whether NAFLD is a risk factor of atherosclerosis beyond its association with the metabolic
syndrome [57]. Studies are available that show an
association between NAFLD and subclinical atherosclerosis. Most of them prove this association
is independent of the metabolic syndrome and traditional cardiovascular risk factors (Table I).
Coronary artery calcification (CAC) is a surrogate marker for atherosclerotic burden and an
independent marker of coronary heart disease
(CHD) risk [58]. Sung et al. analyzed data from
a South Korean occupational cohort of 10,153
individuals who received an ultrasound of the
abdomen for assessment of fatty liver and a cardiac computerized tomography (CT) computed
CAC score. Fatty liver was associated with a CAC
score > 0, independent of all metabolic syndrome
features (OR = 1.21; 95% CI: 1.01–1.45) [59]. An
evaluation of 505 non diabetic, asymptomatic
men free of known CHD showed a positive correlation between hepatic steatosis diagnosed by
ultrasound and CAC quantified by an electron
beam tomography scan. The prevalence of CAC
was higher among patients with hepatic steatosis (52% vs. 37%, p = 0.001). This association was
statistically significant after adjustment for age,
CHD risk factors, and liver enzymes [60].
Another study included 2424 participants from
the Coronary Artery Risk Development in Young
Adult Study [61]. This study used CT to quantify
liver fat, CAC, and abdominal aortic calcification
(AAC). Patients with NAFLD had an increased prevalence of CAC (37.9% vs. 26.0%; p < 0.001) and
AAC (65.1% vs. 49.9%; p < 0.001). The association of NAFLD with CAC and AAC persisted after
adjustment for demographics and health behaviors. However, this association did not reach statistical significance after adjustment for visceral
adipose tissue [61]. A more recent study involved
a cross-sectional analysis of 3796 participants in
the Multi-Ethnic Study of Atherosclerosis (MESA)
study. This study showed that NAFLD is associated
with increased inflammation and CAC independent of traditional risk factors, obesity, and the
metabolic syndrome [62]. There was a graded association between NAFLD, obesity, and the metabolic syndrome with inflammation and CAC.
Measurement of carotid intima-media thickness (CIMT) using ultrasound is a marker of subclinical atherosclerosis. Carotid intima-media
thickness is a strong predictor of future vascular
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Table I. Studies showing association of non-alcoholic fatty liver disease and subclinical atherosclerosis
Author

Year

Country

Study design

Subjects

Vascular
phenotype

OR (95% CI) or
p-value

Results
significant
after regression
analysis

Santos [60]

2007

Brazil

Cross-sectional
analysis

505

CAC

1.49
(1.00–2.21)

Yes

Sung [59]

2012

South
Korea

Cross-sectonal
analysis

10,153

CAC

1.21
(1.01–1.45)

Yes

Vanwagner
[61]

2014

USA

Cross-sectional
analysis

2424

CAC
AAC

CAC: 1.72
(1.29–2.28)
AAC: 1.85
(1.40–2.46)

CAC: No
AAC: No

Rifai [62]

2015

USA

Cross-sectional
analysis

3976

CAC
Inflammation
(hsCRP)

CAC: 1.63
(1.34–1.98)
hsCRP: 2.22
(1.85–2.67)

CAC: Yes
hsCRP: Yes

Thakur [64]

2012

India

Cross-sectional
analysis

80

CIMT

Average CIMT:
4.8 (1.8–12.8)
Maximum CIMT:
5.4 (2.0–14.4)
FMD: 11.7 (1.4–96.5)

Yes

Targher [65]

2005

Italy

Case-control
study

90

CIMT

CIMT values:
1.10 ±0.20 vs.
0.84 ±0.13
(p < 0.001)

Yes

Huang [66]

2011

China

Cross-sectional
analysis

8632

CIMT
baPWV

CIMT: 1.48
(1.17–1.86)
baPWV: 1.50
(1.29–1.75)

CIMT: Yes
baPWV: Yes

Kim [70]

2009

South
Korea

Cross-sectional
analysis

1021

CIMT

2.32
(1.65–3.27)

Yes

Wang [69]

2009

Taiwan

Prospective
cohort study

169

CIMT

ALT (every 10 IU/l
increment)
1.44 (1.09–1.89)

Yes

Agarwal
[68]

2011

India

Prospective
cohort study

124

CIMT

Mean CIMT 0.71
±0.19 mm vs.
0.67 ±0.22,
p = 0.213

Yes

Kang [67]

2012

South
Korea

Cross-sectional
analysis

663

CIMT

1.98
(1.44–2.73)

Yes

Ampuero
[71]

2009–
2012

Meta-analysis

1947

CIMT

2.04
(1.65–2.51)

Yes

Yu [79]

2014

China

Cross-sectional
analysis

1296

baPWV

1321 ±158 cm/s vs.
1244 ±154 cm/s,
p < 0.001

Yes

Li [78]

2014

China

Prospective
cohort study

1225

baPWV

Significant both
with and without
presence of
metabolic syndrome

Yes

Chung [77]

2015

Korea

Cross-sectional
analysis

2954

CAVI

Mild NAFLD:
1.27 (1.02–1.57)
Moderate-severe
NAFLD: 1.78
(1.37–2.31)

Yes

CAC – coronary artery calcium, AAC – abdominal aortic calcification, hsCRP – high-sensitivity C-reactive protein, CIMT – carotid intimamedia thickness, FMD – flow-mediated dilatation, baPWV – brachial-ankle pulse wave velocity, ALT – alanine aminotransferase,
CAVI – cardioankle vascular index, NAFLD – non-alcoholic fatty liver disease.
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events and better predicts risk of stroke compared
to myocardial infarction [63]. A cross-sectional
study in an Indian population showed that subjects with NAFLD had a higher average and maximum CIMT than controls. The presence of NAFLD
was an independent predictor of having a high
average CIMT and high maximum CIMT after adjusting for obesity, the metabolic syndrome, insulin resistance, and lipid parameters [64]. Another
case control study that compared 50 consecutive
patients recruited from clinics with 40 matched
healthy volunteers showed a statistically significant difference in CIMT between patients with
NASH, simple steatosis, and controls. The difference in groups was statistically significant after
adjustment for age, sex, homeostatic model assessment-insulin resistance score, and the metabolic syndrome [65].
A large cross-sectional study on 8632 participants in China revealed a statistically significant
higher CIMT in persons with NAFLD compared
to those without NAFLD [66]. Logistic regression
analysis showed that NAFLD conferred a 35% increased odds of elevated CIMT independent of
conventional risk factors and the presence of the
metabolic syndrome [66]. A larger meta-analysis
included 4 studies [67–70]. This meta-analysis
included 1,947 patients. Pathological CIMT was
present in 35.1% of NAFLD patients compared to
21.8% of patients without NAFLD (p < 0.0001). In
meta-regression analysis, age and body mass index did not alter statistical significance [71].
The cardioankle vascular index (CAVI) represents stiffness of the entire arterial segment
from the aorta to the ankle [72, 73]. Cardioankle
vascular index reflects the progression of arteriosclerosis and is positively related to the severity
of coronary atherosclerosis [74, 75]. Cardioankle
vascular index also predicts carotid arteriosclerosis and stroke [75, 76]. In a cross-sectional
analysis of 2954 subjects, NAFLD was associated
with a 42% increase in the risk of arterial stiffness [77]. The risk of arterial stiffness increased
with the severity of NAFLD. The association was
statistically significant after adjustment for other risk factors including body mass index, waist
circumference, smoking status, diabetes, and hypertension [77].
Another measure of arterial stiffness is the brachial-ankle pulse wave velocity (baPWV). A prospective study included 728 men and 497 women
free of hypertension and diabetes mellitus [78].
These subjects were followed for 5 years. During
the study period, baPWV changes were significantly greater in subjects with NAFLD than in subjects without NAFLD. Multiple regression analysis
revealed that NAFLD is an independent and significant predictor for changes of baPWV [78]. Anoth-

er cross- sectional study in a Chinese population
included 1296 non-obese, non-hypertensive and
non-diabetic young and middle-aged subjects undergoing routine medical check-ups [79]. Subjects
with NAFLD had a significantly higher level of baPWV than the controls (1321 ±158 cm/s vs. 1244
±154 cm/s; p < 0.001). The prevalence of NAFLD
was higher in the increased baPWV group versus the normal baPWV group (29.3% vs. 16.9%;
p < 0.001). Multiple liner logistic regression analysis revealed that NAFLD was positively and independently associated with baPWV [79]. Another
study also showed that subjects with NAFLD had
a higher baPWV as compared to those without
NAFLD (1665 ±424 cm/s vs. 1558 ±430 cm/s;
p < 0.0001) [66]. Logistic regression revealed
a 30% increased odds of elevated baPWV, independent of conventional risk factors and the presence of the metabolic syndrome [66].

Non-alcoholic fatty liver disease and
atherosclerotic cardiovascular disease
Multiple epidemiological studies have linked
NAFLD to increased cardiovascular disease risk
[80, 81] (Table II). A prospective observational
study included 1637 apparently healthy Japanese
men and women followed for a period of 5 years
[15]. Among 1221 participants available for outcome analysis, the incidence of atherosclerotic
cardiovascular disease (CHD, ischemic stroke, and
cerebral hemorrhage) was higher in subjects with
NAFLD at baseline than those without NAFLD.
Multivariate analyses indicated that NAFLD was
a predictor of cardiovascular disease independent
of conventional risk factors (OR = 4.12; 95% CI:
1.58–10.75; p = 0.004) [15].
A large prospective cohort study in a Chinese
university hospital recruited 612 consecutive
patients undergoing coronary angiography [16].
Coronary artery disease was present in 84.6% of
the patients with NAFLD versus 64.1 % without
NAFLD. The association was statistically significant after adjusting for demographics and the
metabolic syndrome (OR = 2.31; 95% CI: 1.46–
3.64). During 87-week follow-up NAFLD did not
predict cardiovascular mortality or morbidity [16].
The association of NAFLD and CAD was investigated in type 2 diabetic patients. A total of 273
diabetic patients without liver disease undergoing
coronary CT angiography were enrolled [82]. Coronary artery disease was defined by the presence
of coronary plaques, and significant CAD was defined as the presence of ≥ 50% stenosis in at least
one coronary artery. No association was found between NAFLD and CAD. However, after adjustment
for age, gender, obesity, hypertension, smoking
status and serum low-density lipoprotein (LDL)
cholesterol as coronary risk factors, NAFLD was
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Table II. Studies showing association of non-alcoholic fatty liver disease with coronary artery disease
Author

Year

Country

Study design

Subjects

Findings

Risk estimates

Hamaguchi
[15]

2007

Japan

Prospective
observational
study

1637
(1221
available
for
analysis)

1. Higher incidence of ASCVD in
NAFLD subjects
2. NAFLD was a predictor of ASCVD
independent of conventional risk
factors

OR = 4.12;
95% CI:
1.58–10.75;
p = 0.004

Wong [16]

2011

China

Prospective
cohort study

612

1. CAD was more common in
patients with NAFLD
2. NAFLD is associated with CAD
independent of other metabolic
factors

OR = 2.31;
95% CI:
1.46–3.64

Idilman
[82]

2007–
2010

Turkey

Crosssectional
retrospective
study

273

NAFLD was associated with
significant CAD (defined as ≥ 50%
stenosis, at least in one coronary
artery) in type 2 diabetics

OR = 2.128;
95% CI:
1.035–4.377

Alper [83]

2008

Turkey

Prospective
cohort study

80

1. More vessels involved among
patients with NAFLD as compared
to patients without NAFLD
2. NAFLD is associated with more
severe CAD

Number of
vessels
(2.5 ±0.9 vs.
1.0 ±1.0;
p < 0.001).
CAD severity
scores
(90.2 ±40.0 vs.
36.4 ±28.9;
p < 0.001)

Acikel [84]

2009

Turkey

Crosssectional
analysis

355

NAFLD has an independent effect
on CAD and Gensini score

CAD (OR =
2.58; p < 0.01)
Gensini Score
(OR = 2.02;
p < 0.05)

Sun [85]

2011

China

Crosssectional
analysis

542

1. NAFLD independently increased
the risk for CAD
2. NAFLD was significantly more
common in patients as CAD
severity increased

OR = 7.585;
95% CI:
4.617–12.461

Arslan [88]

2012

Turkey

Cross-sectional
analysis

151

1. NAFLD was more prevalent
in patients with poor coronary
collateral circulation
2. Mean Rentrop collateral score
was significantly lower in patients
with NAFLD

1. 82.9% vs.
49.4%;
p < 0.001
2. 1.2 ±1.2 vs.
2.1 ±0.9;
p < 0.001

Targher
[14]

2000–
2005

Italy

Prospective
nested casecontrol study

2103

NAFLD was significantly associated
with increased cardiovascular
disease among type 2 diabetics
independent of traditional
risk factors and the metabolic
syndrome

OR = 1.84;
95% CI:
1.4–2.1;
p < 0.001

Pisto [13]

1991–
2009

Finland

Population
based
randomly
recruited
cohort

988

Severe liver fat content predicted
the risk of future cardiovascular
events after adjustment for age,
gender, and study group

HR = 1.92;
95% CI:
1.32–2.80

ASCVD – atherosclerotic cardiovascular disease, NAFLD – non-alcoholic fatty liver disease, CAD – coronary artery disease.

associated with significant CAD in type 2 diabetics
(OR = 2.128; 95% CI: 1.035–4.377) [82].
A prospective study in 80 patients with the
metabolic syndrome undergoing coronary angiography evaluated the association between
NAFLD and CAD severity [83]. Coronary angiogra-

1238

phy showed involvement of more vessels (2.5 ±0.9
vs. 1.0 ±1.0; p < 0.001) and more severe CAD severity scores (Gensini scores, 90.2 ±40.0 vs. 36.4 ±28.9;
p < 0.001) among patients with NAFLD. In multivariate regression analysis, NAFLD was the only
independent factor affecting CAD severity score
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[83]. Another study investigated cross-sectional
analysis of 355 patients undergoing coronary angiography and showed a similar conclusion [84].
Univariate analysis showed that the presence of
NAFLD has independent effects on CAD (OR = 2.58;
p < 0.01) and also independently affects Gensini
score (OR = 2.02; p < 0.05) [84]. Sun et al. enrolled
542 patients planned to undergo coronary angiography [85]. Abdominal computed tomography
(CT) was performed before coronary angiography to detect NAFLD. Logistic regression analysis
showed that the presence of NAFLD independently increased the risk of CAD seen on coronary angiography (OR = 7.585; 95% CI: 4.617–12.461).
Non-alcoholic fatty liver disease was seen significantly more common in patients as the CAD severity increased [85].
Coronary collateral development has been
shown to improve survival in patients with CAD
[86]. The presence of the metabolic syndrome and
associated insulin resistance have been shown to
be associated with poor collateral development
[87]. Arslan et al. enrolled 151 consecutive non-diabetic patients with stable angina pectoris with
more than 95% stenosis in at least one major coronary artery [76]. Non-alcoholic fatty liver disease
was more prevalent in patients with poor collateral development (82.9% vs. 49.4%; p < 0.001). The
mean Rentrop collateral score was significantly
lower in patients with NAFLD (1.2 ±1.2 vs. 2.1
±0.9; p < 0.001). Non-alcoholic fatty liver disease
was significantly related to poor circulation (OR =
6.20; 2.61–14.75) after logistic regression analysis
was performed using factors associated with poor
collateral development [88].
Targher et al. carried out a prospective-nested
case-control study in 2103 type 2 diabetics free
of cardiovascular disease at baseline [14]. During
a 5-year follow-up, 248 participants subsequently
developed nonfatal cardiac event, ischemic stroke
or cardiovascular death. Four hundred ninety-six
subjects that remained free of diagnosed cardiovascular disease were selected as controls.
Non-alcoholic fatty liver disease was significantly
associated with an increased atherosclerotic cardiovascular disease risk (OR = 1.84; 95% CI: 1.4–
2.1; p < 0.001) after adjustment for age, sex, smoking history, diabetes duration, hemoglobin A1c,
LDL cholesterol, liver enzymes, and use of medications. The risk was attenuated but stayed
statistically significant after adjustment for the
metabolic syndrome [14]. Pisto et al. followed
988 Finnish participants from 1991–2009. Patients were divided in three groups based on liver
fat content. During the follow-up period, 13.5%
of participants with non-fatty liver, 24.2% with
moderate liver fat content, and 29.2% with severe fatty liver experienced a cardiovascular event
(p < 0.001). Severe liver fat content predicted the

risk of future cardiovascular event when adjusted for age, gender, and study group (HR = 1.92;
95% CI: 1.32–2.80). The risk remained statistically significant (HR = 1.74, 95% CI: 1.16–2.63)
after further adjustment for smoking, alcohol
consumption, LDL cholesterol, body mass index,
and systolic blood pressure, but disappeared after
further adjustment for the QUICKI (Quantitative
Insulin Sensitivity Check Index) [13].
Non-alcoholic fatty liver disease is associated
with a higher average CIMT, maximum CIMT and
presence of pathological CIMT [64, 65, 71]. Carotid
intima-media thickness predicts the risk of future
atherosclerotic cardiovascular disease including stroke [63]. However, there are inconclusive
data linking NAFLD with stroke. A cross-sectional
study studied the association of acute ischemic
stroke with biochemical markers of NAFLD [89].
Elevated alanine aminotransferase (ALT), ≥ 95th
percentile was used as the criterion for the biochemical presence of inflammatory NAFLD. The
odds ratio for stroke in patients with an elevated ALT was 3.5 (95% CI: 1.7–7.6) and it was 3.3
(95% CI: 1.3–8.4) after adjustment for age, sex,
current smoking, current heavy alcohol intake,
history of hypertension, atrial fibrillation, LDL cholesterol, serum glucose, and serum creatinine [89].
Another case control study included 110 brain
magnetic resonance imaging confirmed ischemic
stroke patients and 110 age-and sex-matched controls [90]. Liver ultrasonography was performed to
detect NAFLD. Non-alcoholic fatty liver disease was
found in 47 (42.7%) of ischemic stroke patients
and 25 (22.7%) of controls. After adjusting for age
and sex, NAFLD was significantly associated with
ischemic stroke (OR = 2.15; 95% CI: 1.25–3.71).
However, the association lost statistical significance after adjusting for confounding risk factors
including body mass index, waist circumference,
smoking, and diabetes mellitus [90].

Treatment of non-alcoholic fatty liver disease
Treatment of NAFLD risk factors is the first line
treatment strategy for NAFLD. Various lifestyle
modifications have shown benefit in NAFLD. These
include weight reduction [91, 92], reduced calorie
intake, exercise alone even without weight loss
[48–50]. A weight reduction achieved by bariatric
procedures has also shown significant benefit in
NAFLD [44–46].
Several studies have studied the effectiveness
of metformin in NAFLD [93]. The results have been
inconsistent with some studies showing benefit
[94, 95], while others not showing any significant
benefit [96, 97]. Based on available evidence, current guidelines do not recommend metformin as
a specific treatment for liver disease in patients
with NAFLD [1].
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Thiazolidinediones (TZDs) increase hepatic lipogenesis and insulin sensitivity by activating
peroxisomal proliferator activated receptor-γ
(PPAR-γ) [98]. Among TZDs, rosiglitazone and pioglitazone have been studied the most. In a randomized placebo-controlled clinical trial, rosiglitazone improved steatosis and transaminase level
despite weight gain at the end of 1 year [99]. Longer therapy did not show additional improvement
in steatosis despite a maintained effect on insulin
sensitivity and transaminase levels [100]. Pioglitazone also showed significant improvement in
fibrosis and hepatocellular injury after 12 months
of treatment [101]. The results of another larger
study did not reach statistical significance [102].
Overall evidence favors use of TZDs; however, caution should be taken in view of their cardiovascular adverse effects.
Liraglutide is a long-acting human glucagon-like peptide-1 (GLP-1) analog. Apart from
glucose-reducing effects, liraglutide is associated
with decreased level of pro-inflammatory cytokines [103]. In a phase 2 clinical trial, liragltide
use was associated with greater odds of resolution of NASH (relative risk 4.3; 95% CI: 1.0–17.7;
p = 0.019) [104]. Another study involving 8 months
of liraglutide use in patients with type 2 diabetes
mellitus and NAFLD has shown significantly reduced CIMT, a marker of subclinical atherosclerosis
[105]. This effect was independent of glucometabolic changes. Further studies are needed to validate these findings and to advocate use of liraglutide in NAFLD.
Among lipid lowering drugs, statins and polyunsaturated fatty acids (PUFA) have shown benefit in NAFLD. In a cross sectional study of 2578
patients undergoing ultrasound, statin use of
more than 2 years duration and body mass index more than 27.5 kg/m2 was associated with
lower prevalence of steatosis (OR = 0.30, 95% CI:
0.11–0.81) [106]. Clinical studies with atorvastatin
have shown improvement in steatosis [107] and
delayed progression of NAFL to NASH [108]. The
current guidelines allow use of statins to treat
dyslipidemia in patients with NAFLD but do not
recommend their use to specifically treat NAFLD
[1]. N-3 PUFA (omega-3 fatty acids) have also
shown promising results in patients with NAFLD
[109]. Based on current evidence, they are not recommended to specifically treat NAFLD, but may
be considered as first line agents to treat hypertriglyceridemia in patients with NAAFLD [1].
Oxidative stress is one of the important hits
in NAFLD pathogenesis. Anti-oxidant property of
Vitamin E has been studied as a possible therapeutic intervention with some success [102]. It is
recommended as a first-line pharmacotherapy for
biopsy-proven NASH in non-diabetic patients [1].
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Other potential treatments include N-acetyl cysteine, vitamin D, ursodeoxycholic acid and pentoxifylline [110]. Further studies are needed to assess
the therapeutic effects of these agents in NAFLD.

Conclusions
The majority of the studies discussed indicate
that NAFLD is associated with cardiovascular disease. NAFLD affects multiple aspects of cardiovascular diseases. Non-alcoholic fatty liver disease is
associated with subclinical atherosclerosis and arterial stiffness. The popular notion used to be that
this association is due to shared risk factors such
as obesity, metabolic syndrome, and diabetes mellitus among others. However, multiple studies have
proved this association to be independent of the
metabolic syndrome and traditional cardiovascular
risk factors. These studies used CAC and CIMT as
markers of subclinical atherosclerosis while CIMT
and baPWV were used as markers of arterial stiffness (Table I). One of the prospective studies also
showed that NAFLD independently and significantly predicted changes in baPWV [78].
Additionally the study by Chung et al. also
showed association between NAFLD and subclinical atherosclerosis in NAFLD severity-dependent
manner [77]. Multivariate analysis showed a severity-dependent relationship between NAFLD
and arterial stiffness (moderate-severe NAFLD:
OR = 1.97, 95% CI: 1.28–3.01, p for trend = 0.002)
in age group less than 55 years [77]. A study evaluating lipid profile among patients with NAFLD
showed that NASH patients had lower levels of
larger LDL1 and increased levels of small dense
LDL3 and LDL4 compared to patients with simple
steatosis [111]. This deranged lipid profile may
partly explain increased risk of atherosclerosis
and cardiovascular disease in patients with NASH
compared to NAFL patients [112].
Epidemiological data exist to link CAD directly
to NAFLD. These studies have shown a higher incidence of CAD, a higher prevalence of CAD, greater
severity of CAD, a higher risk of future cardiovascular event, and increased atherosclerotic cardiovascular disease among subjects with NAFLD as
compared to subjects without NAFLD (Table II).
Most of these studies were adjusted for the presence of conventional risk factors shared by NAFLD
and CAD. Physicians treating NAFLD should be
cognizant of these associations and should actively look out for symptoms of CAD in this population, facilitating early therapeutic interventions.
Arslan et al. showed that NAFLD was associated with poor coronary collateral development [88].
Insulin resistance [59, 80], oxidative stress [9],
worsening inflammatory state [9, 62], and endothelial dysfunction [113] have all been implicated
in the pathogenesis of cardiovascular disease in
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NAFLD. The current understanding is that insulin resistance is responsible for resistance to the
antilipolytic effect of insulin and combined with
visceral and pathological ectopic fat accumulation
of NAFLD lead to an increased availability of free
fatty acids [80]. The increased availability of free
fatty with ongoing chronic subclinical inflammation, increased oxidative stress, and endothelial
dysfunction promotes atherosclerosis and a dysfunctional physiological state with poor cardiovascular outcomes [80, 81]. Even though strong
epidemiological evidence is available linking
NAFLD with subclinical atherosclerosis and atherosclerotic vascular disease, our knowledge of the
biochemical pathways contributing to this association is incomplete. More studies are needed to
understand the underlying biochemical pathways
and markers responsible for above findings which
could lead to development of needed therapeutic
interventions.
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